Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Severin

Showing results (81-90 of 88) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 88 results.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|March 28, 2016
Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHFLicette C Y Liu, Adriaan A Voors, John R Teerlink, et al.
International Journal of Cardiology|January 8, 2018
Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHFMarco Metra, Beth A Davison, Claudio Gimpelewicz, et al.
Anticancer Research|April 13, 2001
Abrogation of G2 checkpoint specifically sensitize p53 defective cells to cancer chemotherapeutic agentsY Luo, S K Rockow-Magnone, M K Joseph, et al.
Journal of Computer-Aided Molecular Design|February 13, 2007
Design and characterization of an engineered gp41 protein from human immunodeficiency virus-1 as a tool for drug discoveryKent D Stewart, Kevin Steffy, Kevin Harris, et al.
Journal of Medicinal Chemistry|March 19, 2004
Discovery of potent inhibitors of dihydroneopterin aldolase using CrystaLEAD high-throughput X-ray crystallographic screening and structure-directed lead optimizationWilliam J Sanders, Vicki L Nienaber, Claude G Lerner, et al.
The American Journal of Cardiology|August 6, 2022
Neutrophil-to-Lymphocyte Ratio and Outcomes in Patients Admitted for Acute Heart Failure (As Seen in the BLAST-AHF, Pre-RELAX-AHF, and RELAX-AHF Studies)Beth A Davison, Koji Takagi, Christopher Edwards, et al.
Lancet (London, England)|November 13, 2012
Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trialJohn R Teerlink, Gad Cotter, Beth A Davison, et al.
Chemical Biology & Drug Design|July 17, 2007
Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategiesJeffrey R Huth, Chang Park, Andrew M Petros, et al.
Pageof 9

Showing results (81-90 of 88) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 88 results.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|March 28, 2016
Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHFLicette C Y Liu, Adriaan A Voors, John R Teerlink, et al.
International Journal of Cardiology|January 8, 2018
Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHFMarco Metra, Beth A Davison, Claudio Gimpelewicz, et al.
Anticancer Research|April 13, 2001
Abrogation of G2 checkpoint specifically sensitize p53 defective cells to cancer chemotherapeutic agentsY Luo, S K Rockow-Magnone, M K Joseph, et al.
Journal of Computer-Aided Molecular Design|February 13, 2007
Design and characterization of an engineered gp41 protein from human immunodeficiency virus-1 as a tool for drug discoveryKent D Stewart, Kevin Steffy, Kevin Harris, et al.
Journal of Medicinal Chemistry|March 19, 2004
Discovery of potent inhibitors of dihydroneopterin aldolase using CrystaLEAD high-throughput X-ray crystallographic screening and structure-directed lead optimizationWilliam J Sanders, Vicki L Nienaber, Claude G Lerner, et al.
The American Journal of Cardiology|August 6, 2022
Neutrophil-to-Lymphocyte Ratio and Outcomes in Patients Admitted for Acute Heart Failure (As Seen in the BLAST-AHF, Pre-RELAX-AHF, and RELAX-AHF Studies)Beth A Davison, Koji Takagi, Christopher Edwards, et al.
Lancet (London, England)|November 13, 2012
Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trialJohn R Teerlink, Gad Cotter, Beth A Davison, et al.
Chemical Biology & Drug Design|July 17, 2007
Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategiesJeffrey R Huth, Chang Park, Andrew M Petros, et al.
Pageof 9